Rubius Therapeutics, Inc. - 10-Q filing on 2022-05-10

Investments and Fair Value of Financial Assets and Liabilities (Tables)

3 Months Ended

Mar. 31, 2022

Investments and Fair Value of Financial Assets and Liabilities

Schedule of investments by security type

As of March 31, 2022, investments by security type consisted of the following (in thousands):


	March 31, 2022
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Credit Losses		Fair Value
U.S. government treasury bills (due within one year)	$	78,470	$	—	$	(57)	$	—	$	78,413
	$	78,470	$	—	$	(57)	$	—	$	78,413

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):


	Fair value measurements at March 31, 2022 using:

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
U.S. government money market funds	$	92,740	$	—	$	—	$	92,740
Investments:
U.S. government treasury bills		—		78,413		—		78,413
	$	92,740	$	78,413	$	—	$	171,153


	Fair value measurements at December 31, 2021 using:

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
U.S government money market funds	$	217,009	$	—	$	—	$	217,009
	$	217,009	$	—	$	—	$	217,009